Drugs / Yttrium Y 90 Glass Microspheres
Yttrium Y 90 Glass Microspheres
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02072356 | Oct 2010 → Jun 2021 | adult hepatocellular carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT03812562 Background | Feb 2019 → Oct 2023 | hepatocellular carcinoma | Northwestern University | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-03-29 | Delcath Systems Inc. | Results Summary of Recent Published Research on Delcath’s PHP Therapy Presented at Society of Surgical Oncology Annual Symposia delcath.com ↗
Karydis showed an overall response rate with PHP of 47%, a >84% disease control rate and hPFS of 9.1 months. |
All press releases naming this drug 8 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yttrium Y 90 Glass Microspheres | “Patients receive yttrium Y 90 glass microspheres intra-arterially (IA) on day 0, and may receive a second dose within 30-90 days of initial treatment.” NCT02072356 ↗1“Radiation: Yttrium Y 90 Glass Microspheres” NCT03812562 ↗ |
| Known as | Y-90 | “yttrium Y 90 glass microspheres (yttrium-90 [Y-90])” NCT03812562 ↗ |
| Known as | yttrium-90 | “yttrium Y 90 glass microspheres (yttrium-90 [Y-90])” NCT03812562 ↗ |
| Modality | Other / unclassified | “This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma.” NCT02072356 ↗ |
| Route | Other | “Patients receive yttrium Y 90 glass microspheres intra-arterially (IA) on day 0” NCT02072356 ↗ |